{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T15:08:49Z","timestamp":1769526529259,"version":"3.49.0"},"reference-count":38,"publisher":"Infectious Disease and Control Branch (IDPCB) - Public Health Agency of Canada","issue":"3\/4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,2]]},"DOI":"10.14745\/ccdr.v43i34a02","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T15:13:21Z","timestamp":1518707601000},"page":"67-71","source":"Crossref","is-referenced-by-count":6,"title":["A shorter treatment regimen for latent tuberculosis infection holds promise for at-risk Canadians"],"prefix":"10.14745","volume":"43","author":[{"given":"C","family":"Pease","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KR","family":"Amaratunga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"GG","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5795","published-online":{"date-parts":[[2017,3,2]]},"reference":[{"key":"key20180215101314_r1","unstructured":"Tuberculosis in Canada 2014 - Pre-release [Internet]. Ottawa: Public Health Agency of Canada; 2016 [cited 2016 Dec 31]. Available from: http:\/\/healthycanadians.gc.ca\/publications\/diseases-conditions-maladies-affections\/tuberculosis-2014-tuberculose\/index-eng.php#a1."},{"key":"key20180215101314_r2","unstructured":"Global tuberculosis report 2016 [Internet]. Geneva: World Health Organization; 2016 [cited 2016 Dec 31]. Available from: http:\/\/apps.who.int\/iris\/bitstream\/10665\/250441\/1\/9789241565394-eng.pdf?ua=1g.pdf?ua=1."},{"key":"key20180215101314_r3","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1183\/09031936.00214014","article-title":"Towards tuberculosis elimination: an action framework for low-incidence countries.","volume":"45","year":"2015","journal-title":"Eur Respir J."},{"issue":"5","key":"key20180215101314_r4","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1183\/09031936.00120908","article-title":"TBNET. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement.","volume":"33","year":"2009","journal-title":"Eur Respir J."},{"issue":"2","key":"key20180215101314_r5","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/oxfordjournals.aje.a121593","article-title":"The prognosis of a positive tuberculin reaction in childhood and adolescence.","volume":"99","year":"1974","journal-title":"Am J Epidemiol."},{"key":"key20180215101314_r6","unstructured":"Menzies D, Alvarez GG, Khan K. Canadian tuberculosis standards, 7th ed. Ottawa: Public Health Agency of Canada; 2014. Chapter 6, Treatment of latent tuberculosis infection; p. 125-52. Available from: http:\/\/www.phac-aspc.gc.ca\/tbpc-latb\/pubs\/tb-canada-7\/tb-standards-tb-normes-ch6-eng.php."},{"issue":"4","key":"key20180215101314_r7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1440-1843.2010.01751.x","article-title":"Treatment of latent tuberculosis infection: an update.","volume":"15","year":"2010","journal-title":"Respirology."},{"key":"key20180215101314_r8","first-page":"935","article-title":"A controlled trial of community-wide isoniazid prophylaxis in Alaska.","volume":"95","year":"1967","journal-title":"Am Rev Respir Dis."},{"issue":"4","key":"key20180215101314_r9","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1016\/j.ijid.2009.05.007","article-title":"Adherence to treatment of latent tuberculosis infection in a clinical population in New York City.","volume":"14","year":"2010","journal-title":"Int J Infect Dis."},{"issue":"17","key":"key20180215101314_r10","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","article-title":"Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis.","volume":"166","year":"2006","journal-title":"Arch Intern Med."},{"key":"key20180215101314_r11","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","article-title":"Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin.","volume":"130","year":"2006","journal-title":"Chest."},{"key":"key20180215101314_r12","unstructured":"Randomized Clinical Trial Comparing 4RIF vs. 9INH for LTBI Treatment-effectiveness. www.clinicaltrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00931736."},{"issue":"5","key":"key20180215101314_r13","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/427802","article-title":"Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.","volume":"40","year":"2005","journal-title":"Clin Infect Dis."},{"key":"key20180215101314_r14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12879-017-2377-x","article-title":"Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses.","volume":"17","year":"2017","journal-title":"BMC Infect Dis."},{"key":"key20180215101314_r15","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1128\/AAC.24.3.457","article-title":"Antibacterial activity of DL 473, a C3-substituted rifamycin derivative.","volume":"24","year":"1983","journal-title":"Antimicrob Agents Chemother."},{"key":"key20180215101314_r16","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(98)11467-8","article-title":"Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid.","volume":"353","year":"1999","journal-title":"Lancet."},{"key":"key20180215101314_r17","unstructured":"Menzies D, Elwood K. Canadian tuberculosis standards, 7th ed. Ottawa: Public Health Agency of Canada; 2014. Chapter 5: Treatment of tuberculosis disease; p. 97-124. Available from: http:\/\/www.phac-aspc.gc.ca\/tbpc-latb\/pubs\/tb-canada-7\/tb-standards-tb-normes-ch5-eng.php."},{"key":"key20180215101314_r18","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1164\/rccm.200512-1953OC","article-title":"Weekly rifapentine\/isoniazid or daily rifampin\/pyrazinamide for latent tuberculosis in household contacts.","volume":"173","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"issue":"1","key":"key20180215101314_r19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","article-title":"New regimens to prevent tuberculosis in adults with HIV infection.","volume":"365","year":"2011","journal-title":"N Engl J Med."},{"issue":"23","key":"key20180215101314_r20","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection.","volume":"365","year":"2011","journal-title":"N Engl J Med."},{"issue":"3","key":"key20180215101314_r21","first-page":"247","article-title":"Tuberculosis Trials Consortium. Treatment for preventing tuberculosis in children and adolescents.","volume":"169","author":"International Maternal Pediatric and Adolescents AIDS Clinical Trials Group","year":"2015","journal-title":"JAMA Pediatr."},{"issue":"7","key":"key20180215101314_r22","first-page":"CD007545","article-title":"Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB.","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"key20180215101314_r23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.7326\/M14-1019","article-title":"Treatment of latent tuberculosis infection a network meta-analysis.","volume":"161","year":"2014","journal-title":"Ann Intern Med."},{"key":"key20180215101314_r24","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1164\/rccm.201111-2076OC","article-title":"Moving toward tuberculosis elimination: implementation of statewide targeted tuberculin testing in Tennessee.","volume":"186","year":"2012","journal-title":"Am J Respir Crit Care Med."},{"issue":"11","key":"key20180215101314_r25","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.","volume":"16","year":"2016","journal-title":"Lancet Infect Dis."},{"issue":"1","key":"key20180215101314_r26","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/cid\/civ766","article-title":"Treatment for tuberculosis infection with 3 months of isoniazid and rifapentine in New York City Health Department clinics.","volume":"62","year":"2016","journal-title":"Clin Infect Dis."},{"key":"key20180215101314_r27","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/cid\/ciw126","article-title":"Factors associated with noncompletion of latent tuberculosis infection treatment: experience from the PREVENT TB trial in the United States and Canada.","volume":"62","year":"2016","journal-title":"Clin Infect Dis."},{"issue":"1","key":"key20180215101314_r28","doi-asserted-by":"crossref","first-page":"ofv220","DOI":"10.1093\/ofid\/ofv220","article-title":"Completion rate and side-effect profile of three-month isoniazid and rifapentine treatment for latent tuberculosis infection in an urban county jail.","volume":"3","year":"2016","journal-title":"Open Forum Infect Dis."},{"key":"key20180215101314_r29","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1353\/hpu.2015.0126","article-title":"Improving treatment completion rates for latent tuberculosis infection: a review of two treatment regimens at a community health center.","volume":"26","year":"2015","journal-title":"J Health Care Poor Underserved."},{"key":"key20180215101314_r30","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/cid\/civ323","article-title":"Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study.","volume":"61","author":"Tuberculosis Trials Consortium","year":"2015","journal-title":"Clin Infect Dis."},{"key":"key20180215101314_r31"},{"key":"key20180215101314_r32","article-title":"A systematic review of adverse events of rifapentine and isoniazid compared to other treatment regimens for latent tuberculosis infection."},{"issue":"12","key":"key20180215101314_r33","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.5588\/ijtld.13.0423","article-title":"Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.","volume":"17","year":"2013","journal-title":"Int J Tuberc Lung Dis."},{"issue":"6","key":"key20180215101314_r34","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5588\/ijtld.14.0052","article-title":"Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices.","volume":"18","year":"2014","journal-title":"Int J Tuberc Lung Dis."},{"issue":"34","key":"key20180215101314_r35","doi-asserted-by":"crossref","first-page":"e4126","DOI":"10.1097\/MD.0000000000004126","article-title":"Impacts of 12-dose regimen for latent tuberculosis infection: treatment completion rate and cost-effectiveness in Taiwan.","volume":"95","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"49","key":"key20180215101314_r36","first-page":"iii","article-title":"Generalisability in economic evaluation studies in healthcare.","volume":"8","year":"2004","journal-title":"Health Technol Assess."},{"key":"key20180215101314_r37","unstructured":"Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT (iAdhere). www.clinicaltrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01582711?term=rifapentine&rank=24."},{"key":"key20180215101314_r38","unstructured":"Taima TB: 3HP Study. www.clinicaltrials.gov. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02689089?term=rifapentine&rank=27."}],"container-title":["Canada Communicable Disease Report"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/migration\/phac-aspc\/publicat\/ccdr-rmtc\/17vol43\/dr-rm43-3-4\/assets\/pdf\/17vol43_3_4-ar-02-eng.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T01:41:06Z","timestamp":1570758066000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.canada.ca\/content\/dam\/phac-aspc\/migration\/phac-aspc\/publicat\/ccdr-rmtc\/17vol43\/dr-rm43-3-4\/assets\/pdf\/17vol43_3_4-ar-02-eng.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,2]]},"references-count":38,"journal-issue":{"issue":"3\/4","published-online":{"date-parts":[[2017,3,2]]},"published-print":{"date-parts":[[2017,3,2]]}},"URL":"https:\/\/doi.org\/10.14745\/ccdr.v43i34a02","relation":{},"ISSN":["1481-8531"],"issn-type":[{"value":"1481-8531","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3,2]]}}}